Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: Clinical synergism and possible immunologic mechanisms

Journal of the American Academy of Dermatology

Volumn 50, Issue 3, 2004, Pages 375-379

  McGinnis, Karen S ^a   Junkins Hopkins, Jacqueline M ^a   Crawford, Glen ^a   Shapiro, Michael ^a   Rook, Alain H ^a   Vittorio, Carmela C ^a,b  

^a Department of Dermatology ^*

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; RECOMBINANT ALPHA INTERFERON; RETINOID;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; LOW DRUG DOSE; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 1542344336     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.10.669     Document Type: Article

References (43)

1. Thestrup-Pedersen K, Hammer R, Kaltoft K, Sogaard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon-alpha-2a alone and in combination with etretinate. Br J Dermatol 1988;118:811-8.
2. Braathen LR, McFadden N. Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alfa-2a. J Dermatol Treat 1989;1:29-32.
3. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991;24:247-52.
4. Dreno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alfa 2a and etretinate. Br J Dermatol 1991;125:456-9.
5. Altomare GF, Capella GL, Pigatto PD, Finzi AF. Intramuscular low dose alpha-2b interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993;32:138-41.
6. Dreno B. Roferon A (interferon alpha 2a) combined with Tigison (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993;11:269-75.
7. Torii H, Kaneko T, Matsuyama T, Nakanishi H, Harada S. Interferon-alpha (IFN-alpha) and etretinate in the treatment of mycosis fungoides. J Dermatol 1994;21:767-70.
8. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, et al. Prospective randomized multicenter clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578-81.
9. Duvic M, Martin A, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial for oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
10. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
11. Talpur R, Ward S, Apisarnthanarax N, Breuer-McHam J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84.
12. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385-409.
13. Foss FM, Sausville EA. Prognosis and staging of cutaneous T cell lymphoma. Hematol Oncol Clin North Am 1995;9:1011-9.
14. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.
15. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002;138:191-8.
16. Fox FE, Kubin M, Cassin M, Niu Z, Trinchieri G, Cooper KD, et al. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1999;19:407-15.
17. Suchin KR, Cassin M, Gottleib SL, Sood S, Cucchiara AJ, Vonderheid EC, et al. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 2001;44:28-32.
18. Lotan R, Dennert G. Stimulatory effects of vitamin A analogues on induction of cell mediated cytotoxicity in vivo. Cancer Res 1979;39:55-8.
19. Denert G, Lotan R. Effects of retinoic acid on the immune system: stimulation of T killer cell induction. Eur J Immunol 1978;8:23-9.
20. Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung HF, Pestka S. Effect of recombinant interferon on cytotoxic activity of NK cells and monocytes. Cell Immunol 1982;67:160-7.
21. Goldfarb RH, Herberman RB. Natural killer cell reactivity: regulatory interactions among phorbol ester, interferon, choleratoxin, and retinoic acid. J Immunol 1981;126:2129-35.
22. Lancillotti F, Giandomenico V, Affabris E, Fiorucci G, Romeo G, Rossi GB. Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 1995;55:3158-64.
23. Majewki S, Szmurlo A, Marczak S, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect of HPV-harboring tumor-cell lines. Int J Cancer 1994;57:81-5.
24. Cheng SX, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001;137:649-52.
25. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330:624-9.
26. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444-50.
27. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. A nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345:224-9.
28. Evans RM. The steroid and thyroid receptor superfamily. Science 1988;240:889-95.
29. Lotan R, Clifford JL. Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells. Biomed Pharmacother 1991;45:145-56.
30. Manglesdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50.
31. Szonday A, Reichert U, Fesus L. Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors. Cell Death Differ 1998;5:4-10.
32. Komuves LG, Hanley K, Lefebvre A-M, Man MQ, Ng DC, Bikle DD, et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 2000;115:353-60.
33. Komuves LG, Hanley K, Man M-Q, Elias PM, Williams ML, Feingold KR. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPAR alpha activators restores tissue homeostasis. J Invest Dermatol 2000;115:361-7.
34. Hanley K, Jiang Y, He SS, Friedman M, Elias PM, Bikle DD, et al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPAR alpha. J Invest Dermatol 1998;110:368-75.
35. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist. J Biol Chem 2000;275:4541-4.
36. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T-cell responses. J Immunol 2000;164:1364-71.
37. Nawa T, Nawa MT, Cai T, Zhang C, Uchimura I, Narumi S, et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 2000;275:406-11.
38. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor gamma activators inhibit IFN gamma-induced expression of the T cell active CXC chemokines IP-10, Mig and I-TAC in human endothelial cells. J Immunol 2000;164:6503-8.
39. Zhang C, Hazarika P, Ni X, Weidner D, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40.
40. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001;15:3263-77.
41. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80.
42. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002;51:58-62.
43. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPAR-gamma and NF-kappa-B expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002;45:147-54.